Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

First Drug Regimen Shown to Prevent AML Relapse

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years among Acute Myeloid Leukemia (AML) patients who receive post-consolidation immunotherapy with Ceplene(TM) (histamine dihydrochloride) in conjunction with low dose interleukin-2 (IL-2). These data were presented on December 9th at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Ceplene is EpiCept's registration stage product candidate for the remission, maintenance and prevention of relapse of patients with AML in first remission, and is currently under late stage review by the European Medicines Evaluation Agency (EMEA).

"These important findings add to the growing body of evidence demonstrating that the combination of Ceplene and low-dose IL-2 is the first drug regimen capable of prolonging leukemia-free survival and preventing relapse among AML patients in first remission," remarked Jack Talley, President and CEO of EpiCept. "While the Phase III study of Ceplene was powered to show a leukemia-free survival benefit over 36 months, these additional data provide confirmation of a lasting leukemia-free benefit for at least five years. We are continuing to work closely with regulators in Europe on our Marketing Authorization Application for Ceplene and remain on track to receive a final decision by the European Commission during the first half of 2008."

Mats L. Brune, MD, Medical Director of the Bone Marrow Transplant Program at the University of Goteborg delivered the findings in a poster presentation entitled, "Post-consolidation Immunotherapy with Histamine Dihydro
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...New research shows while obesity may increase a pe...a healthy diet may have the opposite effect.// In ...rly 1,500 participants for more than 20 years. The...ge were twice as likely to develop dementia later ...
...The path to middle age has taken its toll on activ...ment surgery could become the norm //for many of t...hnique offers hope for active years ahead. Michael...rouching and clicking, kneeling and directing. His...
...Male heart attack patients fare better after havin... patients, say researchers based on results // fro...looked at mortality rates and other factors among...o underwent balloon angioplasty to clear blocked a...
...Patients with rheumatoid arthritis who receive a m...xperience a remission of their disease, finds a ne...signed 111 patients with similar levels of disease...d monthly treatment with oral drugs to fight rheum...
Other Medicine News:
(Date:8/19/2008)...swire-FirstCall/ -- Vical Incorporated,(Nasdaq: V...h the Karolinska,Institutet (KI), a leading Europe...or Infectious Disease Control (SMI), a governmenta...adjuvant with the Biojector(R),2000 needle-free in...,OTCBB: BJCT) for a multivalent preventive DNA vac...
(Date:8/19/2008)... /- VION,PHARMACEUTICALS, I...d,entered into an agreement with the Dutch-Belgian...the "HOVON") to conduct a clinical trial of,laromu...emission-induction,therapy in patients aged 18-65 ...ia (AML) and high-risk myelodysplasia (MDS)., Ala...
(Date:8/18/2008).../PRNewswire-USNewswire/ -- Due to an,exceptionally...s in,southeastern Pennsylvania, the Department of ...ill be stepping up efforts this week to combat the...ely to carry -- the virus., While only one human ...s year (a 27-year-old Montgomery County woman), DE...
(Date:8/18/2008)...re-USNewswire/ -- Boston University and Aubrey,Mil... Human Genetics, Inc.,("CHG") and Director of the ...nounced that CHG will no longer offer testing serv...tics, Inc., These patented tests include tests re... or Connexin 26 mutations, developmental disorders...
Breaking Medicine Technology:Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 2Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 3Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities 2Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities 3Saladax Biomedicals 5 FU Personalized Chemotherapy Management 28PCM 28R 29 29 Assay CE Marked for Distribution in the EU 2457 1Saladax Biomedicals 5 FU Personalized Chemotherapy Management 28PCM 28R 29 29 Assay CE Marked for Distribution in the EU 2457 2Saladax Biomedicals 5 FU Personalized Chemotherapy Management 28PCM 28R 29 29 Assay CE Marked for Distribution in the EU 2457 3Gene mutation improves leukemia drugs effect 22091 1Gene mutation improves leukemia drugs effect 22091 2People with lower incomes lower education levels have higher death rates 22089 1People with lower incomes lower education levels have higher death rates 22089 2Scientists discover DNA knot keeps viral genes tightly corked inside shell 3667 1Scientists discover DNA knot keeps viral genes tightly corked inside shell 3667 2
..., 2007 /PRNewswire-FirstCall/ --,SuperGen Inc. ann...ons at the American Association for Cancer Researc...ese presentations,will focus on data concerning ma...ng its lead tyrosine kinase inhibitor compound,MP...target involved,in cancer cell drug resistance. Pr...
... 2007 -- CytImmune, a,clinical stage nanomedicine...ization of multifunctional, tumor-targeted therapi...at the 43rd American,Society of Clinical Oncology ...poster session will take place from 8:00 am to 12,...mmune will,present the poster abstract entitled "P...
Other Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 2SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 3SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR 4CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
...N 1700 was developed to address hematology needs i... use, low maintenance, closed-tube sampling, small...tures expected in the modern hematology lab. New c...ticated data management, and simplification of dat...
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously.
For physicians looking for a traditional ECG who also want advanced communications with electronic storage features, the Atria 3100 combines the best of both worlds. It maintains the popular compact,
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: